Could a Cure for Alzheimer’s be Invented in the Triangle? Absolutely.

Old people with neurodegenerative diseases
By The Editors of Talking Trials,

Currently, the estimated annual cost of nine common neurological diseases totals to $800 billion, predictably increasing as the elderly population doubles by 2050. More specifically, there is a catastrophic unmet need in Alzheimer’s disease treatment, prevention and clinical research. In a recent segment with WRAL News’ Health Team with Dr. Allen Mask, Worldwide Clinical Trials’ chief operating officer, Peter Benton, discusses Worldwide’s uncommon approach to fighting against neurodegenerative diseases through its recent partnership with Datavant.

Read More

Rater Training and Surveillance: Reducing Alzheimer’s Research Failure Rates

Alzheimer’s disease research
By Rolana Avrumson, MS, Director of Clinical Projects, Clinical Assessment Technologies, Worldwide Clinical Trials,

  Alzheimer’s disease research often fails due to problems with the drug target or the agent being tested. In some clinical cases, however, methodological imprecision is the culprit.1 To avoid pitfalls in methodology, Worldwide implements lessons learned in clinical trials from our long history of tenaciously fighting Alzheimer’s disease.

Read More

Q&A with Natalia Drosopoulou: Important Implications of NIA-AA Framework for Alzheimer’s Disease Research – Part 1 of 3

National Institute of Aging and Alzheimer’s Association Framework for Alzheimer’s Disease Research
By Editors of Talking Trials,

  In 2017, the National Institute of Aging and Alzheimer’s Association (NIA-AA) proposed a common research framework to help clinical investigators establish a research agenda and evaluate the impact of various therapeutics in the Alzheimer’s disease (AD) continuum, and specifically to define and stage AD and facilitate research reporting. 

Read More

How eCOA Simplifies Alzheimer’s Disease Research

Alzheimer’s disease research, electronic Clinical Outcomes Assessments

  Alzheimer’s disease research is taking advantage of new technology, including eCOA. To understand this trend, Talking Trials spoke with Will Tucker, Worldwide Clinical Trials’ Associate Director of Clinical Assessment Technologies (CAT). Will serves as a key leader in the CAT department, managing a highly experienced scale management, rater training, and reliability group that is seamlessly integrated with Worldwide’s Site Feasibility & Recruitment, Project Management, Clinical Operations, and Medical Monitoring groups. As the pharmaceutical industry moves away from paper administration of scales and toward electronic solutions, CAT now partners with industry leaders in electronic Clinical Outcomes Assessments (eCOA) and has expanded its offerings to include eCOA vendor oversight.

Read More

Perspectives on Alzheimer’s Disease Research from Worldwide’s Chief Medical & Scientific Officer

Alzheimer's, U.S. National Alzheimer’s Project Act, Biomarkers

Michael Murphy, M.D., Ph.D., has been on the forefront of Alzheimer’s disease research since the advent of cholinesterase inhibitors as a cognitive therapeutic in the late 1970s. As Chief Medical & Scientific Officer of Worldwide Clinical Trials, Dr. Murphy provides a strategic leadership role in program and protocol design across multiple therapeutic areas, for both interventional and observational research. Dr. Murphy is responsible for the coordination of didactic and experiential training services for the Worldwide Fellowship program, which bears his name. He is the recipient of the Clinical Research & Excellence (CARE) Lifetime Achievement Award for 2017. The award is presented annually to an extraordinary individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career. In addition, PharmaVoice selected him as one of 2017’s 100 Most Inspiring People in the life-sciences industry.

Read More